

Article

Total Syntheses of (+)-Gabosine P, (+)-Gabosine Q, (+)-Gabosine E, (–)-Gabosine G, (–)-Gabosine I, (–)-Gabosine K, (+)-Streptol and (–)-Uvamalol A by a Diversity-Oriented Approach Featuring Tunable Deprotection Manipulation

Po Yuan, Xiaojing Liu, Xing Yang, Yanli Zhang, and Xiaochuan Chen

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b00181 • Publication Date (Web): 09 Mar 2017

Downloaded from <http://pubs.acs.org> on March 9, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.


1
2
3
4
5
6
7 **Total Syntheses of (+)-Gabosine P, (+)-Gabosine Q, (+)-Gabosine E,**
8
9
10 **(-)-Gabosine G, (-)-Gabosine I, (-)-Gabosine K, (+)-Streptol and**
11
12
13 **(-)-Uvamalol A by a Diversity-Oriented Approach Featuring Tunable**
14
15 **Deprotection Manipulation**

16
17
18 Po Yuan, Xiaojing Liu, Xing Yang, Yanli Zhang, and Xiaochuan Chen*

19
20
21 *Key Laboratory of Green Chemistry & Technology of Ministry of Education, College of Chemistry,*

22
23
24 *Sichuan University, Chengdu 610064, PR China*

25
26
27 *E-mail: chenxc@scu.edu.cn



36
37 **Abstract:** A new diversity-oriented approach to C7-cyclitols, which possess a broad spectrum of
38 biological activities, is developed. The key polyoxygenated intermediates with different *O*-protecting
39 groups were accessed by an intramolecular aldol-cyclization of a diketone derived from
40 δ -D-gluconolactone. The versatile intermediates can be easily transformed into structurally different
41 carbasugars based on control of deprotection manipulation. The utility of the robust approach is illustrated
42 by the first syntheses of (+)-gabosines P and Q, as well as the syntheses of several other gabosines and
43 related analogues viz. (+)-gabosine E, (-)-gabosine G, (-)-gabosine I, (-)-gabosine K, (+)-streptol and
44 (-)-uvamalol A. In addition, the absolute configuration of (-)-uvamalol A is assigned by its total
45 synthesis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Many carbasugar-type natural products have a polyoxygenated methyl or hydroxymethyl cyclohexane as a common structural feature, and are known to have a diverse range of biological activities.¹ As a representative family of these C7-cyclitols, gabosines are a class of secondary metabolites isolated from several *Streptomyces* strains. They have been shown to display a wide range of interesting bioactivities such as antibiotic,² anticancer,³ inhibition of cholesterol biosynthesis,² and DNA binding properties.⁴ Some synthetic analogues of gabosines also present interesting and promising biological activities,^{4a} and several derivatives have been described as very potent emerging antitumor agents due to their glutathione *S*-transferases (GST) inhibition activity.⁵

Although the term gabosines was first used in the literature in 1993,² the first isolation of gabosine member, KD16-U1 (identical to gabosine C, **1**), could be traced to the early 1970s.⁶ After gabosines L, N and O (**2-4**) were reported in 2000,^{4a} no new member was found within the next fifteen years. Very recently two new natural cyclitols, named gabosines P and Q (**5** and **6**), were isolated from the culture of *Streptomyces* strain no. 8.⁷ Structurally, **5** and **6** are the monoacylation derivatives of (+)-gabosine E (**7**)² at the different hydroxyl groups (Figure 1). Their absolute configurations were assigned by electronic circular dichroism (ECD). (+)-Gabosine P (**5**) exhibited significant α -glucosidase inhibitory activity with an IC₅₀ values of 9.07 μ M, which was over 70-fold stronger than that of clinical acarbose (IC₅₀ = 663.28 μ M), whereas (+)-gabosine Q (**6**), the acylation regioisomer of (+)-gabosine P, showed no obvious inhibitory activity.⁷ (+)-Gabosine P is a potential leading compound in searching new drugs for the treatment of type 2 diabetes. Some other carbasugars isolated from natural sources, such as (+)-streptol (**8**)⁸ and (-)-uvamalol A (**9**),⁹ display also a structural pattern within the gabosine family.




Figure 1. Several Representative Gabosines and Related Natural Carbasugars.


The gabosines and their natural analogues show high structural diversity due to differences in the unsaturation degree of the ring, the substituent positions, and the relative and absolute configuration of their stereogenic centers. More importantly, these structural alteration, including the change of the acetylation position (e.g. **5** vs **6**), may lead to the significant differences in biological activities. Their structural diversity and promising biological activities have motivated synthetic studies directed to these targets. Up to now, most of the gabosines have already been synthesized by various strategies.^{10,11} However, the syntheses of (+)-gabosines P and Q have not been reported yet. Moreover, the synthesis strategies suitable for a large number of these compounds from common synthetic intermediates are rare hitherto.^{11d,11h,12} Herein, we describe the first synthesis and absolute configuration confirmation of (+)-gabosine P and (+)-gabosine Q via a new diversity-oriented approach. Besides **5** and **6**, the generality versatility of our method can be validated by synthesizing several other representative gabosines and their

analogues including (+)-gabosine **7**,² (-)-gabosine **10**,² (-)-gabosine **11**,^{2,13} (-)-gabosine **12**,² (+)-streptol **8**⁸ and (-)-uvamalol **9**.⁹

Result and Discussion


Our divergent proposal for the synthesis of these gabosine-type cyclitols is shown in Scheme 1. Novel 1,5-diketone **13** with three different types of hydroxyl protecting groups is designed as the key cyclization precursor. The desired carbocyclic framework is constructed via an intramolecular aldol condensation of **13** to furnish common intermediate **14**, in which the OH protecting groups on the required position can be selectively removed for the subsequent modification. After reduction of the carbonyl group, selective cleavage of acetonide might open a rapid access to gabosines P, Q and E, whereas the removal of the PMB or TBS groups prior to isopropylidene acetal would favor the synthesis of (-)-gabosines G, K and (-)-uvamalol **9** respectively. In addition, complete deprotection of the intermediates in one step is feasible to produce (-)-gabosine **11** and (+)-streptol.

Scheme 1. Diversity-Oriented Strategy for the Syntheses of Gabosines and their Analogues.



1
2
3
4
5
6
7 The synthesis of 1,5-diketone **13** commenced from *D*-glucono- δ -lactone (**15**) (Scheme 2). According to
8
9 the previously reported procedure, **15** was converted into the diisopropylidene derivative in high yield,¹⁴
10
11 in which the free α -hydroxy group was subsequently protected as TBS ether to give the known derivative
12
13 **16**.¹⁵ Ester **16** was directly transformed into methyl ketone **17** by *in situ* formation of the Weinreb amide¹⁶
14
15 followed by addition of MeMgBr (82% yield). The terminal isopropylidene acetal in **17** was selectively
16
17 hydrolyzed to afford the diol **18**. After selective protection of primary hydroxyl group as PMB ether, the
18
19 resulting secondary alcohol **19** was oxidized to the target diketone **13**. The key intramolecular aldol
20
21 reaction of dione **13** was investigated next. Under the previous conditions for similar aldol-type
22
23 cyclization (0.3 eq. *L*-proline in DMSO, room temperature, 6 days),¹⁷ our reaction didn't work almost due
24
25 to structural difference of the dione substrates. Even running the reaction with 1 equiv *L*-proline at 50 °C
26
27 for 5 days, a poor yield of aldol product **14** was obtained (11%), along with considerable recovered
28
29 starting material **13** (75%). Although employment of LDA as promoter led to a full consumption of **13**,
30
31 cyclization product **14** was still obtained in low yield (19%).¹⁸ Some other base-mediated reaction
32
33 conditions, including KO^{*t*}Bu,¹⁹ NaH²⁰ and KHMDS,²¹ also led to poor yields or failed to give results.
34
35 Fortunately, when diketone **13** was treated with pyrrolidine and AcOH at room temperature, the aldol
36
37 condensation proceeded smoothly to afford **14** in 88% yield.²²


38
39
40
41
42
43
44
45
46
47
48
49 Although not important for the overall synthesis of the target molecules, the configuration of the tertiary
50
51 hydroxy-bearing C-5 in **14** was assigned by NMR spectroscopic analysis. In its NOESY spectrum, HO-5
52
53 signal ($\delta = 2.33$ ppm) correlated with H-3 signal ($\delta = 4.08$ ppm), and H-7a signal ($\delta = 3.39$ ppm)
54
55 correlated with H-4 signal ($\delta = 3.94$ ppm) respectively. It illustrates the α -configuration of C-5 hydroxyl
56
57 group in the six-member ring. Namely, aldol product **14** is a hydroxyl-protected derivative of valiolone.²³
58
59
60

Scheme 2. Construction of Key Polyhydroxy Cyclic Intermediate **14**.

With the cyclic intermediate **14** in hand, we first aimed the syntheses of gabosines P, Q and E (Scheme 3). Elimination of the tertiary alcohol in **14** with Burgess reagent²⁴ furnished enone **20** in high yield. Selective 1,2-reduction of enone **20** with DIBAL produced a 2.4:1 mixture of diastereoisomeric alcohols **21a** and **21b**, respectively. The stereostructure of major α -alcohol **21a** was subsequently confirmed by its transformation into the natural products including streptol, gabosines P and Q. Thus, the desired isomer **21a** acetylated to give the corresponding acetate **22**, in which the isopropylidene blocking group was then removed with pyridine p-tolenesulfonate (PPTS) in MeOH to afford diol **23**. Chemoselective oxidation of the allyl alcohol functionality in diol **23** was smoothly achieved with the Dess-Martin periodinane to generate enone **24**. Finally, (+)-gabosine P (**5**) was easily obtained via simultaneous removal of PMB and TBS groups. In order to prepare (+)-gabosine Q, TBS was employed to mask the hydroxy group in **21a**.

Following the similar manipulation involving hydrolysis of the acetonide and oxidation of the allyl alcohol, the resulting bis-silyl ether **25** was transformed into enone **27**, which underwent acetylation of the remaining hydroxyl group to afford acetate **28**. **28** and **27** were separately subjected to acid-mediated cleavage of TBS and PMB groups to give (+)-gabosines Q (**6**) and E (**7**). The spectroscopic properties of the synthetic samples (the optical rotation, ^1H and ^{13}C NMR spectral data) were identical to those of the natural products.⁷ The results validated the molecular structures and the absolute configuration of (+)-gabosines P and Q.


Scheme 3. Syntheses of (+)-Gabosines P, Q and E from **14**.



Next, we set out to utilize the above cyclic intermediates to synthesize other gabosine members by adjusting the deprotection sequence (Scheme 4). Most directly, for these protecting groups all are sensitive

to acid, the conversion of intermediates **20** and **21a** into (–)-gabosine I (**11**) and (+)-streptol (**8**) was easily achieved by a one-pot full deprotection respectively. On the other hand, the PMB group in **20** could be selectively removed with DDQ to give primary alcohol **29**, which was converted into the acetate **30** in high yield. Hydrolysis of acetonide and TBS groups gave (–)-gabosine G (**10**) by treatment with aqueous TFA. Luche reduction²⁵ of α,β -unsaturated ketone **30** exhibited inverse stereoselectivity to generate β -hydroxy isomer **31** as the major product (dr = 7.3:1), which underwent the acidic hydrolysis to afford (–)-gabosine K (**12**).


Scheme 4. Syntheses of (–)-Gabosines G, K, I and (+)-Streptol from **20**.



For the further illustration of the utility of this strategy, we turned our attention to the synthesis of (–)-uvamalol A (**9**). (–)-Uvamalol A was isolated from the roots of *Uvaria macrophylla*,⁹ and its absolute

1
2
3
4
5
6
7 configuration was not identified. Up to date, there is only one synthesis of (\pm)-uvamalol A reported by the
8
9 Sureshan group,¹¹ⁱ and its enantioselective synthesis has not been reported yet. It is necessary to unmask
10 the hydroxy functionality at C-2 prior to the rest for the conversion of the polyhydroxylated intermediates
11
12 to (-)-uvamalol A. Although the treatment of **20** with TBAF failed to obtain the corresponding de-TBS
13
14 product, the silyl group in **14** could be removed smoothly under the similar conditions to give α -hydroxyl
15
16 ketone **32** (Scheme 5). After the benzylation of the secondary hydroxyl group, the resulting compound **33**
17
18 was transformed into dehydrated product **34** with Burgess reagent. Removal of PMB ether protecting
19
20 group with DDQ gave primary alcohol **35**, which was subsequently converted into bis-benzoate **36**. Luche
21
22 reduction of enone furnished an inseparable mixture of two diastereoisomers. Fortunately, the inseparable
23
24 isomers were directly subjected to hydrolysis of isopropylidene group resulting in a mixture of
25
26 deprotected products, which were easily separated on column chromatography to give (-)-uvamalol A (**9**)
27
28 (72%) and 1-*epi*-uvamalol A (18%). To the best of our knowledge, this is the first synthesis of optically
29
30 pure uvamalol A. All the spectral data including the optical rotation were found to match with the reported
31
32 data,⁹ and, hence, the absolute configuration of natural (-)-uvamalol A (**9**) could be confirmed to be (1*R*,
33
34 2*S*, 3*S*, 4*R*).

Scheme 5. Synthesis of (-)-Uvamalol A from 14.



Conclusion

In summary, we have developed a general carbasugar synthesis strategy featuring employment of the polyoxygenated aldol-cyclization products with different *O*-protecting groups as versatile intermediates, in which those masked hydroxyl groups can be selectively modified by control of deprotection to achieve syntheses of various C7-cyclitols. The utility of the robust approach has been demonstrated by the first syntheses of (+)-gabosines P and Q, as well as the syntheses of several other structurally different gabosines and related analogues viz. (+)-gabosine E, (-)-gabosine G, (-)-gabosine I, (-)-gabosine K, (+)-streptol and (-)-uvamalol A. In addition, the unknown absolute configuration of (-)-uvamalol A is established. Further exploitation of this strategy in the construction of other cyclohexa(e)noid natural products and their derivatives is in progress.

Experimental Section

1
2
3
4
5
6
7 **General:** Flash chromatography was performed using silica gel (200-300 mesh). Reactions were
8
9 monitored by thin layer chromatography (TLC). Visualization was achieved under a UV lamp (254 nm),
10
11 while Infrared (IR) spectra were recorded on a NEXUS 670 FT-IR (Fourier Transform Infrared)
12
13 Spectrophotometer and are reported in wavenumbers (cm^{-1}). Optical rotations were measured on a
14
15 polarimeter, and are reported as follows: $[\alpha]_{\text{D}}^{\text{T}}$ (c : g/100 mL, in solvent). ^1H and ^{13}C NMR spectra were
16
17 recorded at 400 and 100 MHz with TMS as the internal standard and were calibrated using residual
18
19 undeuterated solvent as an internal reference (CDCl_3 : ^1H NMR = 7.26, ^{13}C NMR = 77.16; CD_3OD : ^1H
20
21 NMR = 3.31, ^{13}C NMR = 49.00). The following abbreviations were used to explain the multiplicities: s =
22
23 singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Coupling constants (J) are reported
24
25 in Hertz (Hz). HRMS spectra were recorded on a LCMS-IT-TOF spectrometer, and methanol or
26
27 dichloromethane was used to dissolve the sample. Solvents for reaction were distilled prior to use:
28
29 dichloromethane (DCM), PhCH_3 and MeCN from CaH_2 , tetrahydrofuran (THF) from Na. Methanol was
30
31 distilled from magnesium, acetone from potassium carbonate, and other reagents were obtained from
32
33 commercial suppliers unless otherwise stated.
34
35
36
37
38
39
40
41
42
43

44 **Compound 17:** To a solution of compound **16** (290 mg, 0.717 mmol) and MeNHOMe-HCl (87.5 mg,
45
46 0.897 mmol) in THF (7 mL) at $-5\text{ }^\circ\text{C}$ was added dropwise MeMgBr (3 M in THF, 1.44 mL, 4.30 mmol).
47
48 The mixture was stirred at $-5\text{ }^\circ\text{C}$ for 90 min, and then allowed to warm slowly to room temperature in the
49
50 low-temperature bath. The reaction was stirred for 14 h at room temperature before saturated aqueous
51
52 NH_4Cl (1.5 mL) and EtOAc (5 mL) were slowly added. The phases were separated and the aqueous phase
53
54 was extracted with EtOAc (3×15 mL). The combined organic layers were dried over anhydrous Na_2SO_4 ,
55
56
57
58
59
60

1
2
3
4
5
6
7 filtered and concentrated under reduced pressure. The residue was purified by flash column
8
9 chromatography (petroleum ether/EtOAc, 16:1) to give ketone **17** (228 mg, 82%) as a colorless crystalline
10
11 solid. m.p. 51 – 52 °C; $[\alpha]_D^{18} +73.5$ (*c* 1.62, CHCl₃); IR (neat) ν_{\max} 2931, 1719, 1375, 1254, 1149, 1074,
12
13 846 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.17 – 4.12 (m, 2H), 4.09 (d, *J* = 2.4 Hz, 1H), 4.04 – 3.92 (m,
14
15 2H), 3.78 (dd, *J* = 8.4, 6.8 Hz, 1H), 2.22 (s, 3H), 1.40 (s, 3H), 1.37 (s, 3H), 1.32 (s, 6H), 0.94 (s, 9H), 0.08
16
17 (s, 3H), 0.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 210.8, 110.4, 109.7, 82.4, 78.6, 77.4, 76.7, 68.3, 27.5,
18
19 27.1, 26.8, 26.4, 25.8, 25.2, 18.2, –4.7, –4.9; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₁₉H₃₆NaO₆Si
20
21 411.2179; Found 411.2178.

22
23
24
25
26
27
28 **Compound 18:** CuCl₂·2H₂O (369 mg, 2.16 mmol) was added to the solution of compound **17** (840 mg,
29
30 2.16 mmol) in CH₃CN (4 mL) at 0 °C. The vigorously stirred mixture was kept at the same temperature
31
32 for 45min. The reaction was quenched with saturated aqueous NaHCO₃ (1 mL). The mixture was filtered
33
34 and the filtrate was extracted with EtOAc (3 × 10 mL). Then the organic phase was dried over anhydrous
35
36 Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (petroleum
37
38 ether/EtOAc, 8:1) to yield diol **18** (301 mg, 91%) as a white solid. m.p. 85 – 87 °C; $[\alpha]_D^{19} +36.7$ (*c* 1.31,
39
40 CHCl₃); IR (neat) ν_{\max} 3448, 2933, 2860, 1713, 1467, 1374, 1254, 1139, 1079, 930, 842, 779 cm⁻¹; ¹H
41
42 NMR (400 MHz, CDCl₃) δ 4.23 (d, *J* = 2.4 Hz, 1H), 4.16 (dd, *J* = 7.6, 2.8 Hz, 1H), 3.95 (t, *J* = 7.4 Hz,
43
44 1H), 3.81 (d, *J* = 10.8 Hz, 1H), 3.70 (dt, *J* = 12.8, 3.6 Hz, 1H), 3.61 (m, 1H), 3.36 (brs, 1H), 2.77 (brs, 1H),
45
46 2.22 (s, 3H), 1.39 (s, 3H), 1.33 (s, 3H), 0.93 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H); ¹³C NMR (100 MHz,
47
48 CDCl₃) δ 211.3, 110.0, 81.7, 78.3, 76.2, 73.3, 64.3, 27.6, 27.3, 26.8, 25.9, 18.3, –4.8, –5.0; HRMS (ESI -
49
50 TOF) *m/z* [M + Na]⁺ calcd for C₁₆H₃₂NaO₆Si 371.1866; Found 371.1867.

1
2
3
4
5
6
7 **Compound 19:** To a solution of compound **18** (235 mg, 0.675 mmol) in DCM (6 mL) was added PPTS
8
9 (17 mg, 0.0675 mmol) and PMBTCA (210 mg, 0.743 mmol). The mixture was stirred at room temperature
10
11 for 2 h, and then evaporated under reduced pressure and purified by flash column chromatography
12
13 (petroleum ether/EtOAc, 8:1) on silica gel to afford the desired product **19** (294 mg, 93%) as a slight
14
15 yellow oil. $[\alpha]_D^{19} +43.0$ (*c* 0.54, CHCl₃); IR (neat) ν_{\max} 3447, 2932, 2859, 1714, 1613, 1514, 1465, 1372,
16
17 1302, 1250, 1137, 1077, 929, 881, 840, 779, 678 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.22 (m, 2H),
18
19 6.90 – 6.82 (m, 2H), 4.53 – 4.46 (m, 2H), 4.22 (dd, *J* = 7.2, 2.4 Hz, 1H), 4.16 (d, *J* = 2.8 Hz, 1H), 4.01 (t, *J*
20
21 = 7.8 Hz, 1H), 3.80 (s, 3H), 3.79 – 3.74 (m, 1H), 3.70 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.51 (dd, *J* = 9.6, 6.0 Hz,
22
23 1H), 2.51 (d, *J* = 4.4 Hz, 1H), 2.21 (s, 3H), 1.40 (s, 3H), 1.32 (s, 3H), 0.94 (s, 9H), 0.05 (s, 3H), 0.03 (s,
24
25 3H); ¹³C NMR (100 MHz, CDCl₃) δ 210.9, 159.5, 130.0, 129.6, 114.0, 110.1, 81.9, 78.7, 75.5, 73.3, 72.6,
26
27 71.6, 55.4, 27.4, 27.3, 26.9, 25.9, 18.3, –4.7, –4.5; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for
28
29 C₂₄H₄₀NaO₇Si 491.2441; Found 491.2439.
30
31
32
33
34
35
36
37
38

39 **Compound 13:** To a stirred solution of (COCl)₂ (106 μ L, 1.21 mmol) in DCM (10 mL) was added DMSO
40
41 (171 μ L, 2.42 mmol) in DCM (0.2 mL) at –78 °C under argon. After 40 min, a solution of **19** (378 mg,
42
43 0.807 mmol) in DCM (2 mL) was slowly added dropwise to the reaction mixture at –78 °C under argon.
44
45 After 60 min, Et₃N (675 μ L, 4.84 mmol) was added dropwise to the above mixture. Then the mixture was
46
47 allowed to warm slowly to room temperature by removing low-temperature reactor. The reaction mixture
48
49 was poured into saturated NaHCO₃ solution, extracted with DCM (3 \times 15 mL), dried over anhydrous
50
51 Na₂SO₄. The evaporated residue was purified by silica gel column chromatography (petroleum
52
53 ether/EtOAc, 8:1) to give diketone **13** (365 mg, 97%) as a slight yellow oil. $[\alpha]_D^{19} +80.0$ (*c* 0.17, CHCl₃);
54
55
56
57
58
59
60

1
2
3
4
5
6
7 IR (neat) ν_{\max} 2932, 2858, 1732, 1613, 1514, 1465, 1379, 1302, 1251, 1138, 1093, 1037, 839, 780 cm^{-1} ; ^1H
8
9 NMR (400 MHz, CDCl_3) δ 7.31 – 7.26 (m, 2H), 6.90 – 6.84 (m, 2H), 4.52 (s, 2H), 4.49 – 4.33 (m, 3H),
10
11 4.25 (dd, $J = 7.6, 3.2$ Hz, 1H), 4.13 (d, $J = 3.2$ Hz, 1H), 3.79 (s, 3H), 2.21 (s, 3H), 1.42 (s, 3H), 1.31 (s,
12
13 3H), 0.93 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 210.2, 206.2, 159.6, 129.9,
14
15 129.1, 114.0, 111.6, 79.8, 79.3, 78.2, 73.1, 72.4, 55.4, 27.2, 26.6, 25.8, 18.2, –4.8, –5.1; HRMS (ESI -
16
17 TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{24}\text{H}_{38}\text{NaO}_7\text{Si}$ 489.2284; Found 489.2280.
18
19
20
21

22 **Compound 14:** To a solution of **13** (1.58 g, 3.39 mmol) in EtOAc (35 mL) was added pyrrolidine (0.3 mL,
23
24 3.56 mmol) and AcOH (0.2 mL, 3.56 mmol) at room temperature under argon. After stirring for 30 h, the
25
26 reaction was evaporated under reduced pressure and purified by flash column chromatography (petroleum
27
28 ether/EtOAc, 8:1) on silica gel to afford **14** (1.39 g, 88%) as a colorless oil. $[\alpha]_{\text{D}}^{19} +4.3$ (c 0.94, CHCl_3);
29
30 IR (neat) ν_{\max} 3455, 2932, 2857, 1733, 1612, 1514, 1466, 1376, 1296, 1249, 1176, 1116, 1024, 1002, 841,
31
32 781, 666 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.26 – 7.21 (m, 2H), 6.91 – 6.85 (m, 2H), 4.51 (d, $J = 12.0$
33
34 Hz, 1H), 4.48 (d, $J = 12.0$ Hz, 1H), 4.26 (d, $J = 10.8$ Hz, 1H), 4.08 (dd, $J = 11.0, 9.4$ Hz, 1H), 3.94 (d, $J =$
35
36 9.6 Hz, 1H), 3.81 (s, 3H), 3.45 (d, $J = 9.0$ Hz, 1H), 3.39 (d, $J = 9.0$ Hz, 1H), 2.58 (s, 2H), 2.33 (s, 1H),
37
38 1.49 (s, 3H), 1.45 (s, 3H), 0.92 (s, 9H), 0.14 (s, 3H), 0.06 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 204.6,
39
40 159.6, 129.8, 129.5, 114.0, 111.9, 79.2, 77.7, 77.4, 73.3, 73.0, 70.9, 55.4, 46.9, 27.4, 26.7, 25.9, 18.8, –4.6,
41
42 –5.1; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{24}\text{H}_{38}\text{NaO}_7\text{Si}$ 489.2284; Found 489.2278.
43
44
45
46
47
48
49
50

51 **Compound 20:** To a solution of **14** (573 mg, 1.22 mmol) in THF (12 mL) was added freshly prepared
52
53 Burgess reagent (625 mg, 2.44 mmol) at room temperature under argon. Then the reaction mixture was
54
55 stirred rapidly at 45 °C for 50 min, extracted with EtOAc (3 × 20mL), dried over anhydrous Na_2SO_4 and
56
57 concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc, 6:1)
58
59
60

1
2
3
4
5
6
7 to give **20** (540 mg, 98%) as a slight yellow oil. $[\alpha]_D^{18} -25.1$ (*c* 0.90, CHCl₃); IR (neat) ν_{\max} 2988, 2932,
8
9 2889, 2856, 1689, 1615, 1586, 1514, 1466, 1379, 1299, 1250, 1148, 1106, 1068, 1037, 967, 928, 890, 842,
10
11 781, 675 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H), 6.91 – 6.86 (m, 2H), 6.11 (q, *J* = 2.0
12
13 Hz, 1H), 4.55 (d, *J* = 11.6 Hz, 1H), 4.51 (d, *J* = 11.6 Hz, 1H), 4.33 – 4.28 (m, 3H), 4.16 (d, *J* = 10.8 Hz,
14
15 1H), 3.81 (s, 3H), 3.82 – 3.77 (m, 1H), 1.47 (s, 3H), 1.44 (s, 3H), 0.94 (s, 9H), 0.19 (s, 3H), 0.13 (s, 3H);
16
17 ¹³C NMR (100 MHz, CDCl₃) δ 197.4, 159.6, 157.7, 129.7, 129.5, 123.1, 114.1, 112.6, 82.5, 78.3, 75.8,
18
19 73.0, 67.0, 55.4, 26.9, 26.6, 25.9, 18.8, –4.4, –5.1; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for
20
21 C₂₄H₃₆NaO₆Si 471.2179; Found 471.2180.
22
23
24
25
26
27

28 **Compound 21a**: To a solution of **20** (238 mg, 0.531 mmol) in CH₂Cl₂ (10 mL) was added dropwise
29
30 DIBAL-H (1.5 M in toluene, 0.71 mL, 1.06 mmol) at –78 °C under argon. After 30 min, saturated
31
32 aqueous sodium potassium tartrate (10 mL) was added and the mixture was diluted with CH₂Cl₂ (5 mL).
33
34 The reaction mixture was warmed to room temperature and kept still for 3 – 5 h until the layers were
35
36 separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layers were
37
38 washed with brine (2 × 10 mL), dried over anhydrous Na₂SO₄ and concentrated. The residue was purified
39
40 by flash chromatography on silica gel (petroleum ether/EtOAc, 8:1) to yield compound **21a** (153 mg, 64%)
41
42 and **21b** (62 mg, 26%) respectively.
43
44
45
46
47

48 **21a**: a colorless oil; $[\alpha]_D^{18} +21.4$ (*c* 0.28, CHCl₃); IR (neat) ν_{\max} 3528, 2931, 2857, 1613, 1513, 1465, 1377,
49
50 1296, 1249, 1169, 1088, 841, 781, 669 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.26 (m, 2H), 6.89 –
51
52 6.85 (m, 2H), 5.78 (dd, *J* = 4.0, 2.4 Hz, 1H), 4.51 (d, *J* = 11.2 Hz, 1H), 4.47 (d, *J* = 11.2 Hz, 1H), 4.33 (t, *J*
53
54 = 4.6 Hz, 1H), 4.19 (dd, *J* = 13.4, 1.4 Hz, 1H), 4.05 (d, *J* = 13.6 Hz, 1H), 4.01 (dd, *J* = 8.0, 1.2 Hz, 1H),
55
56 3.95 (dd, *J* = 10.8, 5.6 Hz, 1H), 3.80 (s, 3H), 3.73 (dd, *J* = 10.8, 8.4 Hz, 1H), 3.27 (s, 1H), 1.43 (s, 3H),
57
58
59
60

1
2
3
4
5
6
7 1.41 (s, 3H), 0.93 (s, 9H), 0.17 (s, 3H), 0.16 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.3, 137.8, 130.4,
8
9 129.5, 123.2, 113.9, 112.1, 78.3, 77.0, 72.5, 71.3, 69.0, 68.3, 55.4, 27.0, 26.8, 25.9, 18.4, -4.3, -4.9;
10
11 HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{24}\text{H}_{38}\text{NaO}_6\text{Si}$ 473.2335; Found 473.2338.
12
13

14
15 **21b**: a colorless oil; $[\alpha]_{\text{D}}^{18}$ -12.1 (c 0.34, CHCl_3); IR (neat) ν_{max} 3443, 2931, 2856, 1613, 1514, 1465, 1376,
16
17 1301, 1249, 1174, 1097, 841, 781, 668 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.29 – 7.26 (m, 2H), 6.90 –
18
19 6.84 (m, 2H), 5.58 (s, 1H), 4.51 (d, J = 11.6 Hz, 1H), 4.47 (d, J = 11.6 Hz, 1H), 4.29 (s, 1H), 4.20 – 4.12
20
21 (m, 2H), 4.05 (d, J = 14.4 Hz, 1H), 3.93 (dd, J = 10.6, 6.2 Hz, 1H), 3.80 (s, 3H), 3.51 (dd, J = 10.8, 8.8 Hz,
22
23 (m, 2H), 4.05 (d, J = 14.4 Hz, 1H), 3.93 (dd, J = 10.6, 6.2 Hz, 1H), 3.80 (s, 3H), 3.51 (dd, J = 10.8, 8.8 Hz,
24
25 1H), 2.01 (d, J = 5.2 Hz, 1H), 1.42 (s, 3H), 1.40 (s, 3H), 0.92 (s, 9H), 0.14 (s, 6H); ^{13}C NMR (101 MHz,
26
27 CDCl_3) δ 159.3, 136.2, 130.4, 129.5, 124.1, 113.9, 111.4, 80.3, 77.9, 77.7, 76.7, 72.4, 67.9, 55.4, 26.9,
28
29 26.7, 26.0, 18.4, -4.2, -4.7; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{24}\text{H}_{38}\text{NaO}_6\text{Si}$ 473.2335; Found
30
31 473.2336.
32
33
34

35
36 **Compound 22**: To a stirred solution of **21a** (206 mg, 0.457 mmol) in CH_2Cl_2 (4.6 mL) was added Et_3N
37
38 (191 μL , 1.37 mmol) and DMAP (5.6 mg, 0.0457 mmol) at room temperature. Then Ac_2O (129.6 μL , 1.37
39
40 mmol) was slowly added dropwise. The reaction was allowed to stir at room temperature for 4 h, extracted
41
42 with CH_2Cl_2 (3×10 mL), dried over anhydrous Na_2SO_4 and concentrated. The residue was purified by
43
44 silica gel column chromatography (petroleum ether/ EtOAc , 16:1) to give **22** (219 mg, 97%) as a colorless
45
46 oil. $[\alpha]_{\text{D}}^{18}$ +78.9 (c 0.23, CHCl_3); IR (neat) ν_{max} 2932, 2896, 2857, 1743, 1613, 1586, 1514, 1466, 1373,
47
48 1301, 1246, 1173, 1102, 1031, 966, 938, 892, 862, 840, 783, 673 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.30
49
50 – 7.24 (m, 2H), 6.90 – 6.84 (m, 2H), 5.69 (t, J = 4.8 Hz, 1H), 5.57 (dd, J = 4.0, 2.2 Hz, 1H), 4.51 (d, J =
51
52 10.8 Hz, 1H), 4.47 (d, J = 11.2 Hz, 1H), 4.17 (dd, J = 14.0, 1.6 Hz, 1H), 4.08 (d, J = 14.0 Hz, 1H), 4.01
53
54 (dd, J = 10.8, 5.2 Hz, 1H), 3.99 – 3.95 (m, 1H), 3.80 (s, 3H), 3.77 (dd, J = 11.2, 8.4 Hz, 1H), 2.07 (s, 3H),
55
56
57
58
59
60

1
2
3
4
5
6
7 1.44 (s, 3H), 1.43 (s, 3H), 0.89 (s, 9H), 0.13 (s, 3H), 0.07 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.4,
8
9 159.4, 140.1, 130.2, 129.5, 120.1, 113.9, 112.2, 78.5, 72.6, 70.5, 70.3, 68.0, 55.4, 26.9, 26.8, 25.8, 21.2,
10
11 18.6, -4.9, -4.9; HRMS (ESI - TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{41}\text{O}_7\text{Si}$ 493.2622; Found 493.2625.
12
13

14
15 **Compound 23:** To a stirred solution of **22** (219 mg, 0.445 mmol) in MeOH (9 mL) was added PPTS (111
16
17 mg, 0.445 mmol) at room temperature. After stirring for 75 min, the reaction was evaporated under
18
19 reduced pressure and purified by flash column chromatography (petroleum ether/EtOAc, 6:1) to afford
20
21 diol **23** (201 mg, quant.) as a colorless oil. $[\alpha]_{\text{D}}^{19}$ +113.5 (c 0.83, CHCl_3); IR (neat) ν_{max} 3451, 2931, 2857,
22
23 1740, 1612, 1586, 1513, 1466, 1369, 1301, 1252, 1176, 1142, 1036, 941, 892, 838, 782, 674 cm^{-1} ; ^1H
24
25 NMR (400 MHz, CDCl_3) δ 7.32 – 7.20 (m, 2H), 6.92 – 6.81 (m, 2H), 5.78 (dd, J = 5.4, 1.4 Hz, 1H), 5.39
26
27 (t, J = 4.8 Hz, 1H), 4.49 (d, J = 11.2 Hz, 1H), 4.44 (d, J = 11.2 Hz, 1H), 4.22 (d, J = 12.8 Hz, 1H), 4.19 –
28
29 4.14 (m, 1H), 4.02 (d, J = 12.4 Hz, 1H), 3.91 (ddd, J = 9.8, 7.6, 2.0 Hz, 1H), 3.80 (s, 3H), 3.66 (dd, J = 9.8,
30
31 4.2 Hz, 1H), 2.99 (d, J = 4.4 Hz, 1H), 2.55 (d, J = 2.0 Hz, 1H), 2.04 (s, 3H), 0.89 (s, 9H), 0.12 (s, 3H),
32
33 0.08 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.6, 159.5, 141.8, 129.9, 129.6, 120.6, 114.0, 73.5, 72.7,
34
35 72.4, 71.1, 69.9, 68.6, 55.4, 25.8, 21.2, 18.2, -4.6, -4.8; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for
36
37 $\text{C}_{23}\text{H}_{36}\text{NaO}_7\text{Si}$ 475.2128; Found 475.2127.
38
39
40
41
42
43
44
45

46
47 **Compound 24:** To a suspension of the above diol **23** (152 mg, 0.336 mmol) and NaHCO_3 (30 mg, 0.353
48
49 mmol) in CH_2Cl_2 (17 mL) was added Dess-Martin periodinane (150 mg, 0.353 mmol). The resulting
50
51 solution was stirred for 30 minutes at 0 $^\circ\text{C}$. The reaction mixture was quenched with saturated $\text{Na}_2\text{S}_2\text{O}_3$
52
53 solution, stirred until clarification, extracted with CH_2Cl_2 (3 \times 20mL), dried over anhydrous Na_2SO_4 and
54
55 concentrated. The residue was purified by column chromatography on silica gel (petroleum ether/ EtOAc,
56
57 8:1) to afford the product **24** (142 mg, 94%) as a colorless oil. $[\alpha]_{\text{D}}^{19}$ +155.5 (c 0.20, CHCl_3); IR (neat)
58
59
60

1
2
3
4
5
6
7 ν_{\max} 3488, 2931, 2857, 1747, 1686, 1613, 1514, 1466, 1370, 1305, 1247, 1147, 1033, 938, 901, 838, 782,
8
9 670 cm^{-1} ; $^1\text{H NMR}$ (400 MHz) δ 7.29 – 7.19 (m, 2H), 6.94 (dt, $J = 6.0, 1.8$ Hz, 1H), 6.91 – 6.85 (m, 2H),
10
11 5.68 (t, $J = 5.0$, 1H), 4.55 – 4.48 (m, 2H), 4.46 (dd, $J = 10.4, 2.4$ Hz, 1H), 4.24 ((dt, $J = 14.8, 1.6$ Hz, 1H),
12
13 4.17 (dd, $J = 14.8, 1.6$ Hz, 1H), 3.90 (dd, $J = 10.0, 4.4$ Hz, 1H), 3.81 (s, 3H), 3.27 (d, $J = 2.4$ Hz, 1H), 2.10
14
15 (s, 3H), 0.89 (s, 9H), 0.14 (s, 3H), 0.08 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 197.8, 170.2, 159.4, 138.7,
16
17 137.6, 129.6, 129.5, 113.9, 74.5, 73.1, 72.4, 67.4, 65.5, 55.3, 25.6, 20.8, 18.2, –4.7, –5.1; HRMS (ESI -
18
19 TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{23}\text{H}_{34}\text{NaO}_7\text{Si}$ 473.1971; Found 473.1968.

20
21
22
23
24
25 **(+)-Gabosine P (5)**: To a stirred solution of **24** (72 mg, 0.16 mmol) in CH_2Cl_2 (4.4 mL) was added TFA
26
27 (0.74 mL) and H_2O (74 μL) at room temperature. The solution was stirred at room temperature for 24 h.
28
29 Concentration of the solution followed by flash chromatography ($\text{CHCl}_3/\text{MeOH}$, 10:1) to yield **(+)-5** (29
30
31 mg, 84%) as a colorless oil. $[\alpha]_{\text{D}}^{17} +275.6$ (c 0.27, MeOH) {lit.⁷ $[\alpha]_{\text{D}}^{21} +106.9$ (c 0.37, MeOH)}; IR (neat)
32
33 ν_{\max} 3379, 2925, 1737, 1689, 1374, 1240, 1141, 1094, 1026, 941, 896 cm^{-1} ; $^1\text{H NMR}$ (400 MHz, MeOD) δ
34
35 6.88 (dt, $J = 5.4, 1.8$ Hz, 1H), 5.67 (t, $J = 4.6$ Hz, 1H), 4.33 (d, $J = 9.6$ Hz, 1H), 4.26 – 4.19 (m, 2H), 3.98
36
37 (dd, $J = 10.0, 4.0$ Hz, 1H), 2.11 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 198.8, 172.2, 142.3, 137.1, 75.5,
38
39 72.3, 69.8, 59.4, 20.7; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_9\text{H}_{12}\text{NaO}_6$ 239.0532; Found
40
41 239.0530.

42
43
44
45
46
47
48 **Compound 25**: To a stirred solution of **21a** (357 mg, 0.793 mmol) in pyridine (8 mL) was added DMAP
49
50 (5 mg, 0.0396 mmol) and TBSOTf (0.55 mL, 2.38 mmol) at 0 °C under argon. After stirring for 5 min, the
51
52 reaction was concentrated by rotary evaporation under reduced pressure. The residue was purified by
53
54 silica gel column chromatography (petroleum ether/EtOAc, 20:1) to give **25** (438 mg, 98%) as a colorless
55
56 oil. $[\alpha]_{\text{D}}^{18} +62.5$ (c 0.20, CHCl_3); IR (neat) ν_{\max} 2932, 2892, 2857, 1613, 1514, 1467, 1377, 1298, 1250,
57
58
59
60

1
2
3
4
5
6
7 1172, 1091, 1040, 967, 944, 907, 869, 836, 779, 669 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.30 – 7.24 (m,
8
9 2H), 6.89 – 6.84 (m, 2H), 5.61 (dd, $J = 4.4, 2.4$ Hz, 1H), 4.52 – 4.46 (m, 2H), 4.32 – 4.28 (m, 1H), 4.17
10
11 (dd, $J = 13.2, 1.2$ Hz, 1H), 4.03 (d, $J = 13.2$ Hz, 1H), 3.93 (m, 1H), 3.89 – 3.83 (m, 2H), 3.81 (s, 3H), 1.44
12
13 (s, 3H), 1.43 (s, 3H), 0.93 (s, 9H), 0.89 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H); ^{13}C
14
15 NMR (100 MHz, CDCl_3) δ 159.3, 135.9, 130.6, 129.4, 125.5, 113.9, 111.6, 77.9, 77.7, 72.6, 72.4, 71.2,
16
17 68.5, 55.4, 27.0, 26.9, 26.3, 26.1, 18.9, 18.4, –4.0, –4.2, –4.2, –4.3; HRMS (ESI - TOF) m/z $[\text{M} + \text{H}]^+$
18
19
20
21
22 calcd for $\text{C}_{30}\text{H}_{53}\text{O}_6\text{Si}_2$ 565.3381; Found 565.3378.
23
24

25 **Compound 26:** To a solution of **25** (429 mg, 0.76 mmol) in MeOH (15 mL) was added PPTS (191 mg,
26
27 0.76 mmol) at room temperature. After stirring for 90 min, the reaction was evaporated under reduced
28
29 pressure and purified by flash column chromatography (petroleum ether/EtOAc, 6:1) to give diol **26** (387
30
31 mg, 97%) as a colorless oil. $[\alpha]_{\text{D}}^{18} +73.1$ (c 0.54, CHCl_3); IR (neat) ν_{max} 3445, 2954, 2931, 2890, 2857,
32
33 1613, 1586, 1514, 1467, 1389, 1361, 1300, 1251, 1174, 1135, 1092, 1037, 953, 900, 866, 835, 778, 710,
34
35 674 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.30 – 7.24 (m, 2H), 6.91 – 6.80 (m, 2H), 5.74 (dd, $J = 5.0, 1.0$
36
37 Hz, 1H), 4.51 – 4.43 (m, 2H), 4.23 – 4.20 (m, 2H), 4.10 (t, $J = 6.0$ Hz, 1H), 4.05 – 3.96 (m, 2H), 3.80 (s,
38
39 3H), 3.54 (dd, $J = 9.0, 3.4$ Hz, 1H), 2.83 (d, $J = 5.2$ Hz, 1H), 2.36 (d, $J = 2.0$ Hz, 1H), 0.92 (s, 9H), 0.88 (s,
40
41 9H), 0.11 (s, 3H), 0.10 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.4, 137.9,
42
43 130.3, 129.5, 125.9, 114.0, 73.3, 72.9, 72.7, 72.5, 70.3, 68.1, 55.4, 26.1, 26.1, 18.4, 18.3, –3.7, –3.8, –4.3,
44
45 –4.6; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{27}\text{H}_{48}\text{NaO}_6\text{Si}_2$ 547.2887; Found 547.2884.
46
47
48
49
50
51
52

53 **Compound 27:** To a stirred solution of diol **26** (235 mg, 0.448 mmol) and NaHCO_3 (41 mg, 0.493 mmol)
54
55 in CH_2Cl_2 (23 mL) was added Dess-Martin periodinane (209 mg, 0.493 mmol) at 0 °C. The resulting
56
57 solution was stirred at 0 °C for 20 minutes. The reaction mixture was quenched with saturated $\text{Na}_2\text{S}_2\text{O}_3$
58
59
60

1
2
3
4
5
6
7 solution, stirred until clarification, extracted with CH₂Cl₂ (3 × 25 mL), dried over anhydrous Na₂SO₄ and
8
9 concentrated. The residue was purified by column chromatography on silica gel (petroleum ether/EtOAc,
10
11 8:1) to afford the enone **27** (229 mg, 98%) as a colorless oil. [α]_D¹⁸ +83.7 (*c* 0.52, CHCl₃); IR (neat) ν_{max}
12
13 3496, 2931, 2891, 2857, 1680, 1613, 1514, 1467, 1387, 1360, 1301, 1251, 1141, 1078, 1037, 967, 938,
14
15 903, 835, 779, 708, 667 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.23 (m, 2H), 6.98 (dt, *J* = 6.0, 1.6 Hz,
16
17 1H), 6.91 – 6.82 (m, 2H), 4.57 (dd, *J* = 10.0, 2.4 Hz, 1H), 4.54 – 4.47 (m, 2H), 4.38 (dd, *J* = 6.0, 3.2 Hz,
18
19 1H), 4.24 (ddd, *J* = 14.4, 1.6, 0.8 Hz, 1H), 4.14 (dd, *J* = 14.4, 1.6 Hz, 1H), 3.81 (s, 3H), 3.74 (dd, *J* = 10.0,
20
21 3.2 Hz, 1H), 3.18 (d, *J* = 2.4 Hz, 1H), 0.93 (s, 9H), 0.89 (s, 9H), 0.15 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H),
22
23 0.09 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 199.1, 159.4, 143.1, 135.6, 130.0, 129.4, 114.0, 74.9, 74.3,
24
25 72.3, 68.2, 65.7, 55.4, 26.1, 25.9, 18.5, 18.3, -3.9, -4.2, -4.4, -4.4; HRMS (ESI - TOF) *m/z* [M + Na]⁺
26
27 calcd for C₂₇H₄₆NaO₆Si₂ 545.2731; Found 545.2733.

28
29
30
31
32
33
34
35 **Compound 28:** To a solution of **27** (95 mg, 0.183 mmol) in CH₂Cl₂ (3.7 mL) was added Et₃N (38.5 μL,
36
37 0.275 mmol) and DMAP (2.2 mg, 0.0183 mmol) at room temperature. Then Ac₂O (26 μL, 0.275 mmol)
38
39 was slowly added dropwise. The reaction was allowed to stir at room temperature for 30 min, extracted
40
41 with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by
42
43 silica gel column chromatography (petroleum ether/EtOAc, 12:1) to give **28** (102 mg, quant.) as a
44
45 colorless oil. [α]_D¹⁸ +86.8 (*c* 0.60, CHCl₃); IR (neat) ν_{max} 2932, 2892, 2858, 1754, 1693, 1613, 1514, 1467,
46
47 1376, 1301, 1251, 1137, 1088, 1036, 967, 839, 778, 668 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.21
48
49 (m, 2H), 6.97 (dt, *J* = 6.0, 1.8 Hz, 1H), 6.91 – 6.84 (m, 2H), 5.71 (d, *J* = 10.0 Hz, 1H), 4.51 (d, *J* = 11.6 Hz,
50
51 1H), 4.48 (d, *J* = 11.6 Hz, 1H), 4.40 (dd, *J* = 6.0, 3.2 Hz, 1H), 4.22 (ddd, *J* = 14.8, 1.6, 0.8 Hz, 1H), 4.09
52
53 (dd, *J* = 14.8, 1.6 Hz, 1H), 4.02 (dd, *J* = 10.4, 2.8 Hz, 1H), 3.80 (s, 3H), 2.17 (s, 3H), 0.90 (s, 9H), 0.89 (s,
54
55
56
57
58
59
60

9H), 0.13 (s, 3H), 0.10 (s, 3H), 0.09 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 193.2, 170.2, 159.4, 141.9, 136.7, 130.1, 129.4, 114.0, 75.5, 72.8, 71.9, 68.2, 65.6, 55.4, 25.9, 25.9, 21.0, 18.3, 18.2, -3.9, -4.0, -4.5, -4.7; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{29}\text{H}_{48}\text{NaO}_7\text{Si}_2$ 587.2836; Found 587.2833.

(+)-Gabosine Q (6): To a stirred solution of **28** (89 mg, 0.159 mmol) in CH_2Cl_2 (2.7 mL) was added TFA (0.9 mL) and H_2O (45 μL) at room temperature. The solution was stirred at room temperature for 30 h. The reaction was concentrated by rotary evaporation under reduced pressure. The residue followed by flash chromatography ($\text{CHCl}_3/\text{MeOH}$, 10:1) to yield (+)-**6** (26 mg, 77%) as a colorless crystalline solid. m.p. 133 – 135 $^\circ\text{C}$; $[\alpha]_{\text{D}}^{16} +138.4$ (c 0.23, MeOH) {lit.⁷ $[\alpha]_{\text{D}}^{21} +75.4$ (c 0.42, MeOH)}; IR (neat) ν_{max} 3380, 2925, 1736, 1691, 1378, 1233, 1097, 1049, 953, 898 cm^{-1} ; ^1H NMR (400 MHz, CD_3OD) δ 7.01 (dt, $J = 6.0, 1.7$ Hz, 1H), 5.59 (d, $J = 10.8$ Hz, 1H), 4.52 – 4.47 (m, 1H), 4.25 (d, $J = 15.6$ Hz, 1H), 4.19 (dd, $J = 15.4, 1.4$ Hz, 1H), 4.00 (dd, $J = 10.8, 4.0$ Hz, 1H), 2.17 (s, 3H); ^{13}C NMR (100 MHz, CD_3OD) δ 194.3, 172.2, 141.9, 140.5, 76.7, 71.1, 67.1, 59.3, 20.7; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_9\text{H}_{12}\text{NaO}_6$ 239.0532; Found 239.0527.

(+)-Gabosine E (7): To enone **27** (65 mg, 0.124 mmol) was added TFA (1.3 mL) and H_2O (65 μL). The solution was stirred at room temperature for 1h. Concentration of the solution followed by flash chromatography ($\text{CHCl}_3/\text{MeOH}$, 2:1) to yield (+)-**7** (18 mg, 81%) as a colorless oil. $[\alpha]_{\text{D}}^{17} +216.8$ (c 0.27, MeOH) {lit.² $[\alpha]_{\text{D}}^{20} +148.0$ (c 0.95, MeOH)}; IR (neat) ν_{max} 3362, 2923, 2870, 1684, 1388, 1185, 1137, 1092, 1052 cm^{-1} ; ^1H NMR (400 MHz, MeOD) δ 6.93 (dt, $J = 5.4, 1.8$ Hz, 1H), 4.51 – 4.47 (m, 1H), 4.35 (d, $J = 10.0$ Hz, 1H), 4.30 – 4.24 (m, 1H), 4.21 (dd, $J = 15.4, 1.0$ Hz, 1H), 3.77 (dd, $J = 10.0, 4.0$ Hz, 1H); ^{13}C NMR (100 MHz, MeOD) δ 199.7, 141.9, 139.9, 75.1, 73.9, 67.1, 59.5; HRMS (ESI - TOF) m/z $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_7\text{H}_{10}\text{NaO}_5$ 197.0426; Found 197.0426.

1
2
3
4
5
6
7 **(-)-Gabosine I (11):** To enone **20** (40 mg, 0.089 mmol) was added TFA (1 mL) and H₂O (50 μL). The
8
9 solution was stirred at room temperature for 5 min. Concentration of the solution followed by flash
10
11 chromatography (CHCl₃/MeOH, 6:1) to yield (-)-**11** (11 mg, 74%) as a colorless oil. $[\alpha]_{\text{D}}^{17} -140.0$ (*c* 0.1,
12
13 MeOH) {lit.² $[\alpha]_{\text{D}}^{20} -61.4$ (*c* 1.0, MeOH)}; IR (neat) ν_{max} 3380, 2924, 2871, 1678, 1432, 1201, 1123, 1066,
14
15 1026 cm⁻¹; ¹H NMR (400 MHz, MeOD) δ 6.15 (q, *J* = 2.0 Hz, 1H), 4.54 – 4.47 (m, 1H), 4.39 – 4.30 (m,
16
17 2H), 4.02 (d, *J* = 10.8 Hz, 1H), 3.60 (dd, *J* = 10.8, 8.0 Hz, 1H); ¹³C NMR (100 MHz, MeOD) δ 199.5,
18
19 167.9, 121.3, 79.4, 78.0, 73.7, 62.0; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₇H₁₀NaO₅ 197.0426;
20
21 Found 197.0426.
22
23
24
25
26

27 **(+)-Streptol (8):** Compound **21a** (80 mg, 0.177 mmol) was dissolved in a mixture of TFA (1 mL) and H₂O
28
29 (50 μL). The resulting solution was stirred at room temperature for 5 min. Concentration of the solution
30
31 followed by purification through flash chromatography (CHCl₃/MeOH, 4:1) to yield (+)-**8** (24 mg, 77%)
32
33 as a colorless oil. $[\alpha]_{\text{D}}^{17} +102.0$ (*c* 0.23, MeOH) {lit.²⁶ $[\alpha]_{\text{D}}^{20} +95.6$ (*c* 0.45, MeOH)}; IR (neat) ν_{max} 3354,
34
35 2922, 1642, 1405, 1261, 1098, 1059, 1014 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.84 – 5.80 (m, 1H), 4.25
36
37 – 4.12 (m, 3H), 3.99 (d, *J* = 7.2 Hz, 1H), 3.73 (dd, *J* = 10.0, 7.2 Hz, 1H), 3.47 (dd, *J* = 10.2, 4.2 Hz, 1H);
38
39 ¹³C NMR (100 MHz, CD₃OD) δ 144.1, 122.9, 74.1, 73.8, 72.6, 67.6, 62.9; HRMS (ESI - TOF) *m/z* [M +
40
41 Na]⁺ calcd for C₇H₁₂NaO₅ 199.0582; Found 199.0580.
42
43
44
45
46
47

48 **Compound 29:** To a stirred solution of **20** (155 mg, 0.345 mmol) in CH₂Cl₂ (26 mL) and phosphate
49
50 buffer (pH = 7.2, 2.6 mL) was added DDQ (235 mg, 1.036 mmol) at 0 °C. The resulting mixture was
51
52 stirred for 12 h at 0 °C. The separated organic layer was washed with saturated aqueous NaHCO₃ and
53
54 saturated aqueous Na₂S₂O₃ (1:1), water and brine successively. The organic layer was concentrated by
55
56 rotary evaporation under reduced pressure. The residue was purified by flash chromatography (petroleum
57
58
59
60

1
2
3
4
5
6
7 ether/EtOAc, 3:1) to yield **29** (100 mg, 88%) as a white solid. m.p. 73 – 75 °C; $[\alpha]_D^{18}$ –42.6 (*c* 0.86,
8
9 CHCl₃); IR (neat) ν_{\max} 3447, 2933, 2857, 1684, 1618, 1468, 1380, 1229, 1147, 1114, 1047, 970, 918, 888,
10
11 842, 781 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.00 (dd, *J* = 4.0, 2.0 Hz, 1H), 4.53 (d, *J* = 17.6 Hz, 1H),
12
13 4.45 (d, *J* = 17.6 Hz, 1H), 4.35 (ddt, *J* = 8.8, 2.4, 1.2 Hz, 1H), 4.18 (d, *J* = 10.8 Hz, 1H), 3.80 (dd, *J* = 11.0,
14
15 8.6 Hz, 1H), 2.41 (s, 1H), 1.48 (s, 3H), 1.45 (s, 3H), 0.94 (s, 9H), 0.18 (s, 3H), 0.13 (s, 3H); ¹³C NMR
16
17 (100 MHz, CDCl₃) δ 197.7, 159.9, 122.5, 112.9, 82.5, 78.3, 75.9, 61.3, 26.9, 26.6, 25.9, 18.8, –4.5, –5.1;
18
19 HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₁₆H₂₈NaO₅Si 351.1604; Found 351.1608.
20
21
22
23
24

25 **Compound 30:** To a stirred solution of **29** (120 mg, 0.365 mmol) in CH₂Cl₂ (8 mL) was added pyridine
26
27 (44 μ L, 0.548 mmol) and DMAP (4.5 mg, 0.0365 mmol) at 0 °C. Then Ac₂O (52 μ L, 0.548 mmol) was
28
29 slowly added dropwise at the same temperature. Then the reaction was stirred at room temperature for 30
30
31 min, extracted with CH₂Cl₂ (3 \times 10 mL), dried over anhydrous Na₂SO₄ and concentrated. The residue was
32
33 purified by silica gel column chromatography (petroleum ether/EtOAc, 8:1) to give **30** (130 mg, 96%) as a
34
35 white solid. m.p. 48 – 49 °C; $[\alpha]_D^{18}$ –57.4 (*c* 0.34, CHCl₃); IR (neat) ν_{\max} 2988, 2933, 2889, 2857, 1753,
36
37 1693, 1624, 1473, 1377, 1226, 1149, 1115, 1080, 1049, 969, 891, 843, 781, 675 cm⁻¹; ¹H NMR (400 MHz,
38
39 CDCl₃) δ 5.91 (dd, *J* = 4.4, 2.0 Hz, 1H), 4.92 (t, *J* = 1.6 Hz, 2H), 4.37 – 4.32 (m, 1H), 4.18 (d, *J* = 11.2 Hz,
40
41 1H), 3.80 (dd, *J* = 11.2, 8.4 Hz, 1H), 2.13 (s, 3H), 1.48 (s, 3H), 1.45 (s, 3H), 0.93 (s, 9H), 0.18 (s, 3H),
42
43 0.12 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.2, 170.2, 155.0, 123.1, 112.9, 82.4, 78.2, 75.5, 61.1, 26.9,
44
45 26.6, 25.9, 20.8, 18.8, –4.5, –5.1; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₁₈H₃₀NaO₆Si 393.1709;
46
47 Found 393.1710.
48
49
50
51
52
53
54
55

56 **(-)-Gabosine G (10):** To **30** (130 mg, 0.351 mmol) was added TFA (3 mL) and H₂O (0.15 mL). The
57
58 solution was stirred at room temperature for 5 min. Concentration of the solution followed by flash
59
60

1
2
3
4
5
6
7 chromatography (CHCl₃/MeOH, 10:1) to yield (–)-**10** (55 mg, 72%) as a colorless oil. $[\alpha]_D^{17} -71.0$ (*c* 0.40,
8 MeOH) {lit.²⁷ $[\alpha]_D^{20} -41.8$ (*c* 1.34, MeOH)}; IR (neat) ν_{\max} 3380, 2925, 1742, 1685, 1426, 1373, 1230,
9 1122, 1053, 915, 886 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 6.00 (q, *J* = 2.0 Hz, 1H), 4.98(dt, *J* = 17.2, 1.6
10 Hz 1H), 4.90(dt, *J* = 17.2, 1.6 Hz 1H) (part of the peak was obscured by the solvent peak), 4.43 – 4.38 (m,
11 1H), 4.04 (d, *J* = 10.8 Hz, 1H), 3.61 (dd, *J* = 10.8, 8.4 Hz, 1H), 2.13 (s, 3H); ¹³C NMR (100 MHz, CD₃OD)
12 δ 199.1, 171.9, 161.5, 122.5, 79.3, 78.0, 73.5, 63.7, 20.6; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for
13 C₉H₁₂NaO₆ 239.0532; Found 239.0534.
14
15
16
17
18
19
20
21
22
23
24

25 **Compound 31:** To a solution of **30** (140 mg, 0.378 mmol) in MeOH (3.8 mL) was added CeCl₃·7H₂O
26 (168 mg, 0.453 mmol) at 0 °C. After stirring at 0 °C for 30 min, NaBH₄ (20 mg, 0.567 mmol) was added.
27
28 The reaction was stirred at 0 °C for 10 min, quenched with saturated aqueous NH₄Cl, evaporated under
29 reduced pressure and purified by flash column chromatography (petroleum ether/EtOAc, 8:1) on silica gel
30 to give **31** (114 mg, 81%) as a colorless oil. $[\alpha]_D^{17} -41.1$ (*c* 0.36, CHCl₃); IR (neat) ν_{\max} 3473, 2987, 2932,
31 2892, 2857, 1746, 1466, 1376, 1230, 1175, 1107, 1073, 1001, 900, 841, 781, 668 cm⁻¹; ¹H NMR (400
32 MHz, CDCl₃) δ 5.53 (tt, *J* = 2.8, 1.6 Hz, 1H), 4.73 – 4.62 (m, 2H), 4.34 – 4.26 (m, 1H), 4.22 – 4.16 (m,
33 1H), 3.95 (dd, *J* = 10.8, 6.4 Hz, 1H), 3.51 (dd, *J* = 10.8, 8.4 Hz, 1H), 2.10 (d, *J* = 6.6 Hz, 1H), 2.09 (s, 3H),
34 1.42 (s, 3H), 1.40 (s, 3H), 0.92 (s, 9H), 0.13 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 134.1, 125.3,
35 111.6, 80.2, 77.7, 77.6, 76.4, 62.3, 26.8, 26.6, 26.0, 21.0, 18.4, –4.2, –4.7; HRMS (ESI - TOF) *m/z* [M +
36 Na]⁺ calcd for C₁₈H₃₂NaO₆Si 395.1866; Found 395.1867.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **(–)-Gabosine K (12):** To a stirred solution of **31** (60 mg, 0.161 mmol) in CH₂Cl₂ (3.2 mL) was added TFA
54 (220 μL) and H₂O (55 μL) at room temperature. The solution was stirred at room temperature for 11 h.
55
56 The reaction was concentrated by rotary evaporation under reduced pressure. The residue followed by
57
58
59
60

1
2
3
4
5
6
7 flash chromatography (CHCl₃/MeOH, 8:1) to yield (–)-**12** (26 mg, 75%) as a colorless oil. [α]_D¹⁷ –61.9 (*c*
8 0.27, MeOH) {lit.²⁸ [α]_D²⁰ –47.9 (*c* 0.52, MeOH)}; IR (neat) ν_{\max} 3380, 2898, 1732, 1375, 1255, 1172,
9 1066, 1032, 968 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 5.60 (m, 1H), 4.73 (d, *J* = 13.2 Hz, 1H), 4.54 (d, *J*
11 = 12.8 Hz, 1H), 4.12 – 4.04 (m, 2H), 3.46 – 3.33 (m, 2H) (part of the peak was obscured by the MeOH
12 peak), 2.07 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 171.1, 134.8, 127.4, 76.1, 75.7, 72.1, 71.6, 63.4, 19.4;
13
14
15
16
17
18
19
20 HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₉H₁₄NaO₆ 241.0688; Found 241.0690..
21

22
23 **Compound 32:** To a stirred solution of **14** (812 mg, 1.74 mmol) in THF (35 mL) was added TBAF (1 M
24 in THF, 1.92 mL, 1.92 mmol) at 0 °C. The resulting mixture was stirred for 25 min at 0 °C before
25 saturated aqueous NH₄Cl (5 mL) and EtOAc (35 mL) were added. The phases were separated and the
26 aqueous phase was extracted with EtOAc (3 × 35 mL). After the organic layer was concentrated under
27 reduced pressure, the residue was purified by flash chromatography (petroleum ether/EtOAc, 2:1) to yield
28 diol **32** (570 mg, 93%) as a colorless oil. [α]_D¹⁸ –19.3 (*c* 0.30, CHCl₃); IR (neat) ν_{\max} 3462, 2987, 2930,
29 1725, 1612, 1586, 1514, 1460, 1377, 1301, 1245, 1175, 1085, 962, 899, 847, 779, 735, 704 cm⁻¹; ¹H NMR
30 (400 MHz, CDCl₃) δ 7.26 – 7.19 (m, 2H), 6.93 – 6.84 (m, 2H), 4.53 (d, *J* = 11.6 Hz, 1H), 4.49 (d, *J* = 11.6
31 Hz, 1H), 4.29 (d, *J* = 10.4 Hz, 1H), 4.02 (d, *J* = 9.2 Hz, 1H), 4.00 – 3.94 (m, 1H), 3.81 (s, 3H), 3.62 (s,
32 1H), 3.48 (d, *J* = 9.2 Hz, 1H), 3.42 (d, *J* = 9.2 Hz, 1H), 2.73 (d, *J* = 16.0 Hz, 1H), 2.67 (d, *J* = 16.0 Hz,
33 1H), 2.42 (s, 1H), 1.53 (s, 3H), 1.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 206.2, 159.6, 129.6, 129.5,
34 114.0, 112.8, 77.9, 77.4, 77.4, 73.3, 72.7, 71.6, 55.4, 45.9, 27.3, 26.7; HRMS (ESI - TOF) *m/z* [M + Na]⁺
35 calcd for C₁₈H₂₄NaO₇ 375.1420; Found 375.1422.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Compound 33:** To a stirred solution of diol **32** (523 mg, 1.48 mmol) in CH₂Cl₂ (30 mL) was added Et₃N
57 (311 μ L, 2.23 mmol) and DMAP (9 mg, 0.0742 mmol) at 0 °C. Then BzCl (205 μ L, 1.78 mmol) was
58
59
60

1
2
3
4
5
6
7 slowly added dropwise. The reaction was stirred at 0 °C for 1 h, extracted with DCM (3 × 30 mL), dried
8
9 over anhydrous Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography
10
11 (petroleum ether/EtOAc, 4:1) to give **33** (664 mg, 98%) as a colorless oil. $[\alpha]_D^{17} +24.2$ (*c* 0.60, CHCl₃); IR
12
13 (neat) ν_{\max} 3477, 3065, 2988, 2932, 2863, 1741, 1609, 1585, 1513, 1455, 1378, 1275, 1176, 1074, 1033,
14
15 847, 780, 711, 672 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.14 – 8.08 (m, 2H), 7.60 – 7.54 (m, 1H), 7.46 –
16
17 7.42 (m, 2H), 7.28 – 7.22 (m, 2H) (part of the peak was obscured by the solvent peak), 6.94 – 6.83 (m,
18
19 2H), 5.65 (d, *J* = 11.6 Hz, 1H), 4.54 (d, *J* = 11.6 Hz, 1H), 4.50 (d, *J* = 11.6 Hz, 1H), 4.42 (dd, *J* = 11.6, 9.6
20
21 Hz, 1H), 4.17 (d, *J* = 9.2 Hz, 1H), 3.82 (s, 3H), 3.51 (d, *J* = 9.2 Hz, 1H), 3.47 (d, *J* = 9.2 Hz, 1H), 2.75 (d,
22
23 *J* = 16.0 Hz, 1H), 2.70 (d, *J* = 16.4 Hz, 1H), 2.54 (s, 1H), 1.53 (s, 3H), 1.51 (s, 3H); ¹³C NMR (100 MHz,
24
25 CDCl₃) δ 199.0, 165.7, 159.6, 133.5, 130.2, 129.6, 129.5, 129.4, 128.4, 114.0, 112.9, 78.6, 78.5, 74.0, 73.3,
26
27 72.7, 71.1, 55.4, 47.1, 27.2, 26.8; HRMS (ESI - TOF) *m/z* [M + Na]⁺ calcd for C₂₅H₂₈NaO₈ 479.1682;
28
29 Found 479.1679.

30
31
32
33
34
35
36
37
38 **Compound 34:** To a solution of **33** (532 mg, 1.17 mmol) in THF (23 mL) was added freshly prepared
39
40 Burgess reagent (597 mg, 2.34 mmol) at room temperature. Then the reaction mixture was refluxed at
41
42 70 °C for 20 min, extracted with EtOAc (3 × 20mL), dried over anhydrous Na₂SO₄ and concentrated. The
43
44 residue was purified by silica gel column chromatography (petroleum ether/EtOAc, 4:1) to give enone **34**
45
46 (506 mg, 99%) as a colorless oil. $[\alpha]_D^{18} +6.2$ (*c* 0.50, CHCl₃); IR (neat) ν_{\max} 3066, 2988, 2929, 2856, 1731,
47
48 1689, 1613, 1514, 1452, 1378, 1344, 1271, 1248, 1176, 1148, 1100, 1074, 1032, 968, 927, 830, 776, 710
49
50 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.0Hz, 2H), 7.60 – 7.54 (m, 1H), 7.45 (t, *J* = 7.6Hz, 2H),
51
52 7.28 (d, *J* = 8.0 Hz, 2H), 6.90 (d, *J* = 8.0 Hz, 2H), 6.25 (d, *J* = 1.2 Hz, 1H), 5.72 (d, *J* = 12.0 Hz, 1H), 4.62
53
54 – 4.49 (m, 3H), 4.38 (s, 2H), 4.16 (dd, *J* = 11.4, 8.6 Hz, 1H), 3.82 (s, 3H), 1.51 (s, 3H), 1.49 (s, 3H); ¹³C
55
56
57
58
59
60

1
2
3
4
5
6
7 NMR (100 MHz, CDCl₃) δ 191.9, 165.7, 159.6, 158.5, 133.5, 130.3, 129.5, 129.4, 129.4, 128.5, 122.8,
8
9 114.1, 113.6, 79.2, 77.0, 76.1, 73.1, 66.8, 55.4, 26.7, 26.7; HRMS (ESI - TOF) m/z [M + Na]⁺ calcd for
10
11 C₂₅H₂₆NaO₇ 461.1576; Found 461.1575.
12
13

14
15 **Compound 35:** To a stirred solution of enone **34** (574 mg, 1.31 mmol) in CH₂Cl₂ (130 mL) and phosphate
16
17 buffer (pH = 7.2, 13 mL) was added DDQ (892 mg, 3.93 mmol) at 0 °C. Then the resulting mixture was
18
19 stirred for 9 h at room temperature. The separated organic layer was washed with saturated aqueous
20
21 NaHCO₃ and saturated aqueous Na₂S₂O₃ (1:1), water and brine successively. The organic layer was
22
23 concentrated by rotary evaporation under reduced pressure. The residue was purified by flash
24
25 chromatography (petroleum ether/EtOAc, 2:1) to yield **35** (371 mg, 89%) as a yellow-green crystalline
26
27 solid. m.p. 139 – 141 °C; [α]_D¹⁸ +14.8 (*c* 0.43, CHCl₃); IR (neat) ν_{\max} 3459, 3067, 2989, 2933, 1731, 1688,
28
29 1617, 1452, 1381, 1323, 1272, 1230, 1177, 1147, 1098, 1064, 969, 919, 843, 767, 711, 646 cm⁻¹; ¹H NMR
30
31 (400 MHz, CDCl₃) δ 8.11 (dt, *J* = 8.0, 1.6 Hz, 2H), 7.61 – 7.56 (m, 1H), 7.48 – 7.42 (m, 2H), 6.16 (dd, *J* =
32
33 4.0, 2.0 Hz, 1H), 5.73 (d, *J* = 11.6 Hz, 1H), 4.65 – 4.58 (m, 2H), 4.54 (d, *J* = 18.0 Hz, 1H), 4.19 (dd, *J* =
34
35 11.8, 8.6 Hz, 1H), 2.22 (s, 1H), 1.53 (s, 3H), 1.50 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 192.0, 165.8,
36
37 160.4, 133.6, 130.3, 129.3, 128.5, 122.4, 113.8, 79.3, 77.1, 76.3, 61.2, 26.8, 26.7; HRMS (ESI - TOF) m/z
38
39 [M + Na]⁺ calcd for C₁₇H₁₈NaO₆ 341.1001; Found 341.1004.
40
41
42
43
44
45
46
47

48
49 **Compound 36:** To a stirred solution of **35** (80 mg, 0.251 mmol) in CH₂Cl₂ (6 mL) was added DIPEA (66
50
51 μ L, 0.377 mmol) and DMAP (3.1 mg, 0.0251 mmol) at 0 °C. Then BzCl (35 μ L, 0.302 mmol) was slowly
52
53 added dropwise at 0 °C. The reaction was stirred at room temperature for 30 min, quenched with saturated
54
55 aqueous NaHCO₃, extracted with DCM (3 \times 10 mL), dried over anhydrous Na₂SO₄ and concentrated. The
56
57 residue was purified by silica gel column chromatography (petroleum ether/EtOAc, 8:1) to give **36** (80 mg,
58
59
60

75%) as a colorless oil. $[\alpha]_D^{17} -24.6$ (*c* 0.17, CHCl_3); IR (neat) ν_{max} 3066, 2988, 2928, 1729, 1692, 1623, 1602, 1585, 1492, 1451, 1378, 1315, 1270, 1226, 1176, 1149, 1103, 1027, 971, 931, 839, 803, 775, 710 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.18 – 8.06 (m, 4H), 7.69 – 7.55 (m, 2H), 7.54 – 7.38 (m, 4H), 6.17 (dd, *J* = 4.2, 2.2 Hz, 1H), 5.77 (d, *J* = 12.0 Hz, 1H), 5.33 – 5.27 (m, 1H), 5.27 – 5.20 (m, 1H), 4.69 (dd, *J* = 8.4, 2.4 Hz, 1H), 4.25 (dd, *J* = 11.8, 8.6 Hz, 1H), 1.55 (s, 3H), 1.53 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 191.8, 165.7, 155.9, 133.8, 133.6, 130.3, 129.9, 129.3, 129.2, 128.8, 128.5, 122.9, 114.0, 79.2, 77.0, 76.0, 61.4, 26.8, 26.7; HRMS (ESI - TOF) *m/z* $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{NaO}_7$ 445.1263; Found 445.1260.

(-)-Uvamalol A (9): To a solution of **36** (37 mg, 0.0877 mmol) in MeOH (1.7 mL) was added $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (39 mg, 0.105 mmol) at 0 °C. After stirring at 0 °C for 30 min, NaBH_4 (5 mg, 0.132 mmol) was added at 0 °C. The reaction was stirred for 5 min, quenched with saturated aqueous NH_4Cl , evaporated under reduced pressure and purified by flash column chromatography (petroleum ether/EtOAc, 6:1) on silica gel to give the mixture of two diastereoisomers. The mixture (34 mg, 0.08 mmol) was dissolved in MeOH (1 mL), and PPTS was added (20 mg, 0.08 mmol) at room temperature. After stirring for 10 h, the reaction was evaporated under reduced pressure and purified by flash column chromatography (petroleum ether/EtOAc, 1:1) to give (-)-**9** (24 mg, 72% over two steps) as a white powder. m.p. 136 – 138 °C; $[\alpha]_D^{17} -73.7$ (*c* 0.30, MeOH) {lit.⁹ $[\alpha]_D^{23} -78.0$ (*c* 0.24, MeOH)}; IR (neat) ν_{max} 3413, 2922, 1713, 1602, 1449, 1274, 1177, 1114, 1069, 1022, 963, 858, 805, 710 cm^{-1} ; ^1H NMR (400 MHz, CD_3OD) δ 8.16 – 8.03 (m, 4H), 7.65 – 7.58 (m, 2H), 7.53 – 7.45 (m, 4H), 5.81 (brs, 1H), 5.22 (dd, *J* = 10.8, 8.4 Hz, 1H), 5.04 (d, *J* = 13.6 Hz, 1H), 4.88 (d, *J* = 13.6 Hz, 1H) (part of the peak was obscured by the solvent peak), 4.47 (d, *J* = 8.4 Hz, 1H), 4.36 (d, *J* = 8.0 Hz, 1H), 3.78 (dd, *J* = 10.8, 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CD_3OD) δ 168.00, 167.6, 136.8, 134.4, 134.1, 131.8, 131.4, 130.8, 130.6, 129.7, 129.4,

1
2
3
4
5
6
7 128.6, 78.7, 75.8, 73.6, 71.0, 65.1; HRMS (ESI - TOF) m/z $[M + Na]^+$ calcd for $C_{21}H_{20}NaO_7$ 407.1107;

8
9 Found 407.1103.

10 11 **Associated Content**

12 13 14 15 **Supporting Information**

16
17
18 Copies of 1H and ^{13}C NMR spectral data. This material is available free of charge via the Internet at
19
20
21 <http://pubs.acs.org>.

22 23 24 **Author Information**

25 26 **Corresponding Author**

27
28
29 *E-mail: chenxc@scu.edu.cn

30 31 **Notes**

32
33
34 The authors declare no competing financial interest.

35 36 37 **Acknowledgments**

38
39 This work was supported by grants from the National Natural Science Foundation of China (21172153,
40
41 21321061). We thank the Comprehensive Training Platform of Specialized Laboratory, College of
42
43 Chemistry, Sichuan University, as well as Prof. Xiaoming Feng group for spectral data measurement.

44 45 46 47 **References and Footnotes**

- 48
49 (1) (a) Das, M.; Manna, K. *Curr. Bioact. Compd.* **2015**, *11*, 239–248. (b) Vogel, P. *Chimia* **2001**, *55*,
50
51 359–365. (c) Arjona, O.; Gómez, A. M.; López, J. C.; Plumet, J. *Chem. Rev.* **2007**, *107*, 1919–2036. (d)
52
53 Marco-Contelles, J. *Eur. J. Org. Chem.* **2001**, *2001*, 1607–1618. (e) Mahmud, T. *Nat. Prod. Rep.* **2003**,
54
55 *20*, 137–166. (f) Witte, M.; Kallemeijn, W. W.; Aten, J.; Li, K.-Y.; Strijland, A.; Donker-Koopman,
56
57
58
59
60

- 1
2
3
4
5
6
7 W. E.; Van Den Nieuwendijk, A. M. C. H.; Bleijlevens, B.; Kramer, G.; Florea, B. I.; Hooibrink, B.;
8
9 Hollak, C. E. M.; Ottenhoff, R.; Boot, R. G.; Van Der Marel, G. A.; Overkleeft, H. S.; Aerts, J. M. F.
10
11 G. *Nat. Chem. Biol.* **2010**, *6*, 907–913. (g) Kallemeijn, W. W.; Li, K.-Y.; Witte, M. D.; Marques, A. R.
12
13 A.; Aten, J.; Scheij, S.; Jiang, J.; Willems, L. I.; Voorn-Brouwer, T. M.; Van Roomen, C. P. A. A.;
14
15 Ottenhoff, R.; Boot, R. G.; Van Den Elst, H.; Walvoort, M. T. C.; Florea, B. I.; Codee, J. D. C.; Van
16
17 Der Marel, G. A.; Aerts, J. M. F. G.; Overkleeft, H. S. *Angew. Chem. Int. Ed.* **2012**, *51*, 12529–12533.
18
19
20
21
22 (2) Bach, G.; Breiding-Mack, S.; Grabley, S.; Hammam, P.; Hütter, K.; Thiericke, R.; Uhr, H.; Wink, J.;
23
24 Zeeck, A. *Liebigs Ann. Chem.* **1993**, *1993*, 241–250.
25
26
27
28 (3) (a) Huntley, C. F. M.; Hamilton, D. S.; Creighton, D. J.; Ganem, B. *Org. Lett* **2000**, *2*, 3143–3144. (b)
29
30 Kamiya, D.; Uchihata, Y.; Ichikawa, E.; Kato, K.; Umezawa, K. *Bioorg. Med. Chem. Lett.* **2005**, *15*,
31
32 1111–1114.
33
34
35
36 (4) (a) Tang, Y. Q.; Maul, C.; Höfs, R.; Sattler, I.; Gabley, S.; Feng, X.-Z.; Zeeck, A.; Thiericke, R. *Eur. J.*
37
38 *Org. Chem.* **2000**, *2000*, 149–153. (b) Maier, A.; Maul, C.; Zerlin, M.; Grabley, S.; Thiericke, R. *J.*
39
40 *Antibiot.* **1999**, *52*, 952–959.
41
42
43
44 (5) (a) Wang, C.-H.; Wu, H. T.; Cheng, H. M.; Yen, T.-J.; Lu, I.-H.; Chang, H. C.; Jao, S.-C.; Shing, T. K.
45
46 M.; Li, W.-S. *J. Med. Chem.* **2011**, *54*, 8574–8581; (b) Shing, T. K. M.; Wu, H. T.; Kwok, H. F.; Lau,
47
48 C. B. S. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7562–7565.
49
50
51
52 (6) Tatsuka, K.; Tschuyia, T.; Mikami, M.; Umezawa, H.; Naganawa, H. *J. Antibiot.* **1974**, *27*, 579–586.
53
54
55
56 (7) Wei, J.; Liu, L.-L.; Dong, S.; Li, H.; Tang, D.; Zhang, Q.; Xue, Q.-H.; Gao, J.-M. *Bioorg. Med. Chem.*
57
58 *Lett.* **2016**, *26*, 4903–4906.
59
60 (8) Isogai, A.; Sakuda, S.; Nakayama, J.; Watanabe, S.; Suzuki, A. *Agric. Biol. Chem.* **1987**, *51*,

- 1
2
3
4
5
6
7 2277–2279.
8
9
10 (9) Wang, S.; Zhang, P.-C.; Chen, R.-Y.; Dai, S.-J.; Yu, S.-S.; Yu, D.-Q. *J. Asian Nat. Prod. Res.* **2005**, *7*,
11 687–694.
12
13
14 (10)(a) Mac, D. H.; Chandrashekhar, S.; Gree, R. *Eur. J. Org. Chem.* **2012**, *2012*, 5881–5895, and
15 references therein. (b) Bayón, P.; Figueredo, M. *Chem. Rev.* **2013**, *113*, 4680–4707, and references
16 therein.
17
18
19
20
21
22 (11) For recent syntheses of gabosines, see: (a) Tibhe, G. D.; Macias, M. A.; Pandolfi, E.; Suescun, L.;
23 Schapiro, V. *Synthesis* **2017**, *49*, 565–570. (b) Mondal, S.; Sureshan, K. M. *J. Org. Chem.* **2016**, *81*,
24 11635–11645. (c) Vulovic, B.; Kolarski, D.; Bihelovic, F.; Matovic, R.; Gruden, M. *Org. Lett.* **2016**,
25 *18*, 3886–3889. (d) Fresneda, M. Á.; Alibés, R.; Bayón, P.; Figueredo, M. *Eur. J. Org. Chem.* **2016**,
26 *2016*, 3568–3574. (e) Raju, G.; Rao, M. V.; Rao, B. V. *J. Carbohydr. Chem.* **2016**, *35*, 150–160. (f)
27 Vidyasagar, A.; Sureshan, K. M. *Eur. J. Org. Chem.* **2014**, *2014*, 2349–2356. (g) Babu, D. C.; Rao, C.
28 B.; Venkatesham, K.; Selvam, J. J. P.; Venkateswarlu, Y. *Carbohydr. Res.* **2014**, *388*, 130–137. (h)
29 Fresneda, M. Á.; Alibés, R.; Font, J.; Bayón, P.; Figueredo, M. *Org. Biomol. Chem.* **2013**, *11*,
30 6562–6568. (i) Mondal, S.; Prathap, A.; Sureshan, K. M. *J. Org. Chem.* **2013**, *78*, 7690–7700.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 (12) Toribio, G.; Marjanet, G.; Alibes, R.; de March, P.; Font, J.; Bayon, P.; Figuedero, M. *Eur. J. Org.*
47 *Chem.* **2011**, *2011*, 1534–1543.
48
49
50
51 (13) Lubineau, A.; Billaut, I. *J. Org. Chem.* **1998**, *63*, 5668–5671.
52
53
54 (14)(a) Fernandes, R. A.; Chavan, V. P.; Mulay, S. V.; Manchoju, A. *J. Org. Chem.* **2012**, *77*,
55 10455–10460. (b) Long, D. D.; Smith, M. D.; Martín, A.; Wheatley, J. R.; Watkin, D. G.; Müller, M.;
56 Fleet, G. W. J. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1982–1998.
57
58
59
60

- 1
2
3
4
5
6
7 (15) Hu, S.-G.; Hu, T.-S.; Wu, Y.-L. *Org. Biomol. Chem.* **2004**, *2*, 2305–2310.
8
9
10 (16) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* **1981**, *22*, 3815–3818.
11
12 (17)(a) Shing, T. K. M.; Cheng, H. M. *Org. Biomol. Chem.* **2009**, *7*, 5098–5102. (b) Shing, T. K. M.;
13
14 Cheng, H. M.; Wong, W. F.; Kwong, C. S. K.; Li, J.; Lau, C. B. S.; Leung, P. S.; Cheng, C. H. K. *Org.*
15
16 *Lett.* **2008**, *10*, 3145–3148.
17
18
19 (18) Fukuda, Y.; Sakurai, M.; Okamoto, Y. *Tetrahedron Lett.* **2000**, *41*, 8505–8508.
20
21
22 (19) Snyder, S. A.; Wespe, D. A.; von Hof, J. M. *J. Am. Chem. Soc.* **2011**, *133*, 8850–8853.
23
24
25 (20) van Wyk, A. W. W.; Lobb, K. A.; Caira, M. R.; Hoppe, H. C.; Davies-Coleman, M. T. *J. Nat. Prod.*
26
27 **2007**, *70*, 1253–1258.
28
29
30 (21) Cichowicz, N.; Kaplan, W.; Khomutnyk, Y.; Bhattarai, B.; Sun, Z.; Nagorny, P. *J. Am. Chem. Soc.*
31
32 **2015**, *137*, 14341–14348.
33
34
35 (22)(a) Banerjee, S.; Santra, S. *Tetrahedron Lett.* **2009**, *50*, 2037–2040. (b) Christoffers, J.; Scharl, H. *Eur.*
36
37 *J. Org. Chem.* **2002**, *2002*, 1505–1508.
38
39
40 (23)(a) Asamizu, S.; Xie, P.; Brumsted, C. J.; Flatt, P. M.; Mahmud, T. *J. Am. Chem. Soc.* **2012**, *134*,
41
42 12219–12229. (b) Floss, H. G.; Lee, S.; Tornus, I. U.S. Patent 6,150,568, November 21, 2000.
43
44
45 (24) Burgess, E. M.; Penton Jr., H. R.; Taylor, E. A. *J. Org. Chem.* **1973**, *38*, 26–31.
46
47
48 (25) Luche, J.-L. *J. Am. Chem. Soc.* **1978**, *100*, 2226–2227.
49
50
51 (26) Shing, T. K. M.; Chen, Y.; Ng, W.-L. *Tetrahedron* **2011**, *67*, 6001–6005.
52
53
54 (27) Shing, T. K. M.; Cheng, H. M. *J. Org. Chem.* **2007**, *72*, 6610–6613.
55
56
57 (28) Shing, T. K. M.; Cheng, H. M. *Synlett* **2010**, *1*, 142–144.
58
59
60